首页 | 本学科首页   官方微博 | 高级检索  
     

食管癌术后淋巴结转移对生存率的影响和放射治疗的意义
引用本文:Xiao ZF,Yang ZY,Wang LH,Zhang HX,Feng QF,Chen DF,Zhou ZM,Zhang DC,Sun KL,Cheng GY,He J. 食管癌术后淋巴结转移对生存率的影响和放射治疗的意义[J]. 中华肿瘤杂志, 2004, 26(2): 112-115
作者姓名:Xiao ZF  Yang ZY  Wang LH  Zhang HX  Feng QF  Chen DF  Zhou ZM  Zhang DC  Sun KL  Cheng GY  He J
作者单位:1. 100021,北京,中国医学科学院中国协和医科大学肿瘤研究所肿瘤医院放射治疗科
2. 100021,北京,中国医学科学院中国协和医科大学肿瘤研究所肿瘤医院胸外科
摘    要:目的 分析淋巴结转移个数对生存率的影响及放射治疗的意义。方法 495例食管癌根治性手术切除患者,随机分为单一手术组(275例)和术后放疗组(220例),根据淋巴结转移的个数分为3组:A组无淋巴结转移,占47.2%;B组淋巴结转移个数1~2枚,占29.5%;C组淋巴结转移个数≥3枚,占23.2%。结果(1)相同T分期(T3)时,A、B、C三组的5年生存率分别为52.6%、28.8%和10.9(P=0.0000);在C组,单一手术和术后放疗者的5年生存率分别为0和19.3%(P=0.0336)。(2)在淋巴结阳性组(B C组),单一手术和术后放疗者的胸内淋巴结转移率分别为35.9%和21.2%(P=0.014),锁骨上淋巴结转移率分别为19.7%和4.4%(P=0.000);在淋巴结阴性组(A组),单一手术和术后放疗的胸内淋巴结转移率分别为27.8%和10.3%(P=0.003);A、B、C三组的腹腔淋巴结转移率分别为3.9%、9.4%和17.5%(P=0.000)。血行转移率以C组最高,为27.8%。结论 淋巴结转移个数是影响食管癌生存率的因素之一。淋巴结转移个数≥3枚时,血行转移率高,是全身化疗的指征。术后放疗降低了放疗部位淋巴结转移率,明显提高了C组生存率。

关 键 词:食管癌术 淋巴结转移 生存率 放射治疗 手术

Influence of the number of lymph node metastasis on survival and significance of postoperative radiotherapy for esophageal carcinoma
Xiao Ze-fen,Yang Zong-yi,Wang Lü-hua,Zhang Hong-xing,Feng Qin-fu,Chen Dong-fu,Zhou Zong-mei,Zhang De-chao,Sun Ke-lin,Cheng Gui-yu,He Jie. Influence of the number of lymph node metastasis on survival and significance of postoperative radiotherapy for esophageal carcinoma[J]. Chinese Journal of Oncology, 2004, 26(2): 112-115
Authors:Xiao Ze-fen  Yang Zong-yi  Wang Lü-hua  Zhang Hong-xing  Feng Qin-fu  Chen Dong-fu  Zhou Zong-mei  Zhang De-chao  Sun Ke-lin  Cheng Gui-yu  He Jie
Abstract:OBJECTIVE: To analyze the influence of the number of lymph node metastasis on survival and prophylactic postoperative radiotherapy after radical resection of thoracic esophageal carcinoma. METHODS: Four hundred and ninety-five patients with thoracic esophageal squamous cell cancer who had undergone radical resection were randomly divided into surgery group alone (S, 275) and surgery plus radiotherapy group (S + R, 220). The patients were classified into three groups: Group A: 234 patients (47.2%) without lymph node involvement; Group B: 146 patients (29.5%) with 1 to 2 involved lymph nodes and Group C: 115 patients (23.2%) with >or= 3 involved lymph nodes. RESULTS: 1. The 5-year survival rate in Groups A, B and C for the same T stage (T3) was 52.6%, 28.8% and 10.9%, respectively (P = 0.0000); the 5-year survival rate in group C was 0% in S group and 19.3% in S + R group (P = 0.0336); 2. In the positive lymph node group, the metastatic rate of intra-thoracic and supraclavicular lymph node was 35.9% and 21.2% in S group and 19.7% and 4.4% in S+R group (P = 0.014 and P = 0.000). In the negative lymph node group, the metastatic rates of intra-thoracic lymph node was 27.8% in S group and 10.3% in S + R group (P = 0.003). The metastatic rate of intra-abdominal lymph node in Groups A, B and C was 3.9%, 9.4% and 17.5%, respectively (P = 0.0000). The occurrence of hematogenous metastasis was most frequent in group C (27.8%) with >or= 3 positive lymph nodes. CONCLUSION: 1. The number of metastatic lymph node is one of the important factors which affects the survival of thoracic esophageal carcinoma. 2. Chemotherapy might be given to the patients with three or more lymph nodes involved who have the possibility of developing hematogenous metastasis. Postoperative radiotherapy can reduce the occurrence of intra-thoracic and supraclavicular lymph node metastasis and improve the survival of patients with three or more lymph nodes involvement.
Keywords:Esophageal neoplasms/surgery  Esophageal neoplasms/radiotherapy  Lymphatic metastasis
本文献已被 CNKI 维普 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号